MannKind Q2 FY26 net loss widens to $19.03 million; revenue rises 43% to $109.37 million

Reuters2026/08/05 20:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MannKind posted Q2 revenue of USD 109.37 million, up 43% year over year.
Operating results swung to an operating loss of USD 350,000 from operating income.
Net results turned to a loss of USD 19.03 million, or USD 0.06 per share, from net income.
Furoscix net sales were USD 22.19 million; Afrezza net sales fell 7% to USD 17.02 million.
FDA cleared Afrezza for ages 6+; Furoscix ReadyFlow autoinjector won approval, expected to reach market in late August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051601PRIMZONEFULLFEED9804492) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MannKind Q2 FY26 net loss widens to $19.03 million; revenue rises 43% to $109.37 million

You may also like

Crypto prices